Journal of Food and Nutrition Research
ISSN (Print): 2333-1119 ISSN (Online): 2333-1240 Website: http://www.sciepub.com/journal/jfnr Editor-in-chief: Prabhat Kumar Mandal
Open Access
Journal Browser
Go
Journal of Food and Nutrition Research. 2014, 2(8), 491-498
DOI: 10.12691/jfnr-2-8-10
Open AccessArticle

Effect of the Synbiotic (B. animalis spp. lactis Bb12 + Oligofructose) in Obese Subjects. A Randomized, Double-Blind, Controlled Clinical Trial

Francisca Peña1, Maria Luisa Mizgier1, Pamela Morales1, Israel Rios1, Catalina Carrasco-Pozo2, Erik Diaz3, Oscar Brunser1 and Martin Gotteland1

1Laboratory of Microbiology and Probiotics, Institute of Nutrition and Food Technology (INTA), University of Chile, El Libano 5524, Macul, Santiago, Chile

2Department of Nutrition, Faculty of Medicine, University of Chile, Independencia 1027, Independencia, Santiago, Chile

3Laboratory of Energy Metabolism, INTA, University of Chile, El Libano 5524, Macul, Santiago, Chile

Pub. Date: August 14, 2014

Cite this paper:
Francisca Peña, Maria Luisa Mizgier, Pamela Morales, Israel Rios, Catalina Carrasco-Pozo, Erik Diaz, Oscar Brunser and Martin Gotteland. Effect of the Synbiotic (B. animalis spp. lactis Bb12 + Oligofructose) in Obese Subjects. A Randomized, Double-Blind, Controlled Clinical Trial. Journal of Food and Nutrition Research. 2014; 2(8):491-498. doi: 10.12691/jfnr-2-8-10

Abstract

Rats fed high fat diets have alterations of their intestinal microbiota, gut barrier function, circulating lipopolysaccharide (LPS) levels and biomarkers of oxidative stress, inflammation, and glucose/insulin metabolism, resulting in a higher risk of type-2 diabetes. These deleterious effects are prevented by antibiotics or prebiotics. The aim of this study was to determine whether the administration of a synbiotic improves metabolic alterations and low grade inflammation in obese subjects. A randomized, double-blind, controlled clinical trial (www.ClinicalTrials.gov, Access Number NCT01235026) was carried out in 40 obese patients. Subjects were distributed in two groups to receive 8g oligofructose + 1 g of lyophilized Bifidobacterium lactis Bb12 (1010 CFU/g) or 9g maltodextrin as placebo, twice a day for six weeks. Body composition, blood lipids, antioxidant capacity of plasma, biomarkers of inflammation (usCRP, IL-6) and LPS exposure (LPS-Binding Protein, LBP, and sCD14), areas under curves of glycemia and insulinemia and fecal microbiota (qPCR) were quantified at baseline and after treatment. 38 subjects (34.8 ± 9.2y; BMI: 36.7 ± 5.3 kg.m-2) completed the study. A positive correlation was observed at baseline between usCRP, IL-6, LBP, sCD14 and the percentage of body fat; correlations also existed between usCRP, IL-6 and LBP values while sCD14 only correlated with IL-6. Compared with placebo, the administration of synbiotic increased the fecal levels of Bifidobacterium spp. but did not affect body composition, lipid profile, antioxidant status and areas under curves of glycemia and insulinemia, nor the plasma concentrations of usCRP, IL-6 and LBP. Plasma concentrations of sCD14 were significantly lower after treatment in the symbiotic group compared with the placebo 3 group (5.98 μg/ml [5.01-6.96] vs. 7.26 [6.34-8.09] μg/ml (Means [CI95%), respectively; p=0.043). The synbiotic increased fecal bifidobacteria in obese subjects without improvement the biochemical, inflammatory and metabolic markers; more studies are required to elucidate the role of the symbiotic on plasma sCD14.

Keywords:
obesity Bifidobacterium lactis Bb12 oligofructose intestinal microbiota lipopolysaccharide sCD14

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Shoelson, S.S., Herrero, L., Naaz, A. Obesity, inflammation, and insulin resistance. Gastroenterology, 132, 2169-80. 2007.
 
[2]  Miranda, J.J., Herrera, V.M., Chirinos, J.A., Gómez, L.F., Perel, P., Pichardo, R., et al. Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American Consortium of Studies in Obesity (LASO). PLoS One 8:e54056.
 
[3]  Zhao, L. The gut microbiota and obesity: from correlation to causality. Nature Reviews Microbiology, 11, 639-47. 2013.
 
[4]  Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 444, 1027-31. 2006.
 
[5]  Backhed, F., Ding, H., Wang, T., Hooper, L.V., Koh, G.Y., Nagy, A., Semenkovich, C.F., Gordon, J.I. The gut microbiota as an environmental factor that regulates fat storage. Proceedings of the National Academy of Sciences USA, 101, 15718-23. 2004.
 
[6]  Ley, R.E., Backhed, F., Turnbaugh, P., Lozupone, C.A., Knight, R.D., Gordon, J.I. Obesity alters gut microbial ecology. Proceedings of the National Academy of Sciences USA, 102, 11070-5. 2005.
 
[7]  Ley, R.E., Turnbaugh, P.J., Klein, S., Gordon, J.I. Microbial ecology: human gut microbes associated with obesity. Nature, 444, 1022-3. 2006.
 
[8]  Brignardello, J., Morales, P., Diaz, E., Romero, J., Brunser, O., Gotteland, M. Pilot study: alterations of intestinal microbiota in obese humans are not associated with colonic inflammation or disturbances of barrier function. Alimentary, Pharmacology and Therapeutics, 32, 1307-14. 2010.
 
[9]  Armougom, F., Henry, M., Vialettes, B., Raccah, D., Raoult, D. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and methanogens in anorexic patients. PLoS One 4: e7125.
 
[10]  Balamurugan, R., George, G., Kabeerdoss, J., Hepsiba, J., Chandragunasekaran, A.M., Ramakrishna, B.S. Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children. British Journal of Nutrition, 103, 1-4. 2009.
 
[11]  Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R.S., Bartelsman, J.F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology, 143, 913-6. 2012.
 
[12]  Hildebrandt, M.A., Hoffmann, C., Sherrill-Mix, S.A., Keilbaugh, S.A., Hamady, M., Chen, Y.Y., Knight, R., et al. High fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology, 137, 1716-24. 2009.
 
[13]  Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes, 56, 1761-72. 2007.
 
[14]  14. Cani, P.D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A.M., Delzenne, N.M., Burcelin, R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes, 57, 1470-81. 2008.
 
[15]  Lindberg, A.A., Weintraub, A., Zähringer, U., Rietschel, E.T. Structure-activity relationships in lipopolysaccharides of Bacteroides fragilis. Review of Infectious Diseases, 12, Suppl 2, S133-41. 1990.
 
[16]  Zhao, L. The gut microbiota and obesity: from correlation to causality. Nature Reviews Microbiology, 11, 639-47. 2013.
 
[17]  Erridge, C., Attina, T., Spickett, C.M., Webb, D.J. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. American Journal of Clinical Nutrition, 86, 1286-92. 2007.
 
[18]  Delzenne, N.M., Neyrinck, A.M., Bäckhed, F., Cani, P.D. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nature Reviews Endocrinology, 7, 639-46. 2011.
 
[19]  Cani, P.D., Neyrinck, A.M., Fava, F., Knauf, C., Burcelin, R.G., Tuohy, K.M., et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxinaemia. Diabetologia, 50, 2374-83. 2007.
 
[20]  Macfarlane, S., Cleary, S., Bahrami, B., Reynolds, N., Macfarlane, G.T. Synbiotic consumption changes the metabolism and composition of the gut microbiota in older people and modifies inflammatory processes: a randomised, double-blind, placebo-controlled crossover study. Alimentary, Pharmacology and Therapeutics, 38, 804-16. 2013.
 
[21]  Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of the American Medical Association, 285, 2486-97. 2001.
 
[22]  Benzie, I.F., Strain, J.J. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Analytical Biochemistry, 239, 70-6. 1996.
 
[23]  Nadkarni, M.A., Martin, F.E., Jacques, N.A., Hunter, N. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology, 148, 257-266. 2002.
 
[24]  Rinttila, T., Kassinen, A., Malinen, E., Krogius, L., Palva, A. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. Journal of Applied Microbiology, 97, 1166-77. 2004.
 
[25]  Walter, J., Hertel, C., Tannock, G.W., Lis, C.M., Munro, K., Hammes, W.P. Detection of Lactobacillus, Pediococcus, Leuconostoc, and Weissella species in human feces by using group-specific PCR primers and denaturing gradient gel electrophoresis. Applied Environmental Microbiology, 67, 2578-85. 2001.
 
[26]  Kok, R.G., de Waal, A., Schut, F., Welling, G.W., Weenk, G., Hellingwerf, K.J. Specific detection and analysis of a probiotic Bifidobacterium strain in infant feces. Applied Environmental Microbiology, 62, 3668-72. 1996.
 
[27]  Wang, R.F., Cao, W.W., Cerniglia, C.E. PCR detection and quantitation of predominantanaerobic bacteria in human and animal fecal samples. Applied Environmental Microbiology, 62, 1242-7. 1996.
 
[28]  Leber, B., Tripolt, N.J., Blattl, D., Eder, M., Wascher, T.C., Pieber, T.R., Stauber, R., Sourij, H., Oettl, K., Stadlbauer, V. The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: an open label, randomized pilot study. European Journal of Clinical Nutrition, 66, 1110-5. 2012.
 
[29]  Verdam, F.J., Fuentes, S., de Jonge, C., Zoetendal, E.G., Erbil, R., Greve, J.W., Buurman, W.A., de Vos, W.M., Rensen, S.S. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity, 21, E607-15. 2013.
 
[30]  Carabin, I.G., Flamm, W.G. Evaluation of safety of inulin and oligofructose as dietary fiber. Regulatory Toxicology and Pharmacology 30: 268-82. 1999.
 
[31]  Didari, T., Solki, S., Mozaffari, S., Nikfar, S., Abdollahi, M. A systematic review of the safety of probiotics. Expert Opinion on Drug Safety; 13: 227-39. 2014.
 
[32]  Brunser, O., Gotteland, M. Prebiotics and probiotics in human health: an overview. In Press in: "Bioactive foods in health promotion: probiotics and prebiotic." Watson R and Preedy V, Ed. Academic press, Kidlingto, UK, 2010.
 
[33]  Salazar, N., Ruas-Madiedo, P., Kolida, S., Collins, M., Rastall, R., Gibson, G., de Los Reyes-Gavilán, C.G. Exopolysaccharides produced by Bifidobacterium longum IPLA E44 and Bifidobacterium animalis subsp. lactis IPLA R1 modify the composition and metabolic activity of human faecal microbiota in pH-controlled batch cultures. International Journal of Food Microbiology, 135, 260-7. 2009.
 
[34]  Gonzalez-Quintela, A., Alonso, M., Campos, J., Vizcaino, L., Loidi, L., Gude, F. Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity. PLoS One 8 (1): e54600. 2013.
 
[35]  Stehle, J.R., Leng, X., Kitzman, D.W., Nicklas, B.J., Kritchevsky, S.B., High, K.P. Lipopolysaccharide-binding protein, a surrogate marker of microbial translocation, is associated with physical function in healthy older adults. The Journals of Gerontology Serie A Biological Sciences Medical Sciences, 67, 1212-8. 2012.
 
[36]  Dunstan, J.A., Roper, J., Mitoulas, L., Hartmann, P.E., Simmer, K., Prescott, S.L. The effect of supplementation with fish oil during pregnancy on breast milk immunoglobulin A, soluble CD14, cytokine levels and fatty acid composition. Clinical and Experimental Allergy, 34, 1237-42. 2004.
 
[37]  Safavi, M., Farajian, S., Kelishadi, R., Mirlohi, M., Hashemipour, M. The effects of synbiotic supplementation on some cardio-metabolic risk factors in overweight and obese children: a randomized triple-masked controlled trial. International Journal of Food Sciences and Nutrition, 64, 687-93. 2013.
 
[38]  Sanz, Y., Santacruz, A. Probiotics and prebiotics in metabolic disorders and obesity. In: Bioactive Foods in Promoting Health: Probiotics and Prebiotics; Watson RR and Preedy VR, Editors. Elsevier: 237-58. 2010.
 
[39]  Laitinen, K., Poussa, T., Isolauri, E. Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota Group. Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomized controlled trial. British Journal of Nutrition, 101, 1679-87. 2009.
 
[40]  Ilmonen J, Isolauri E, Poussa T, Laitinen K. 2011. Impact of dietary counseling and probiotic intervention on maternal anthropometric measurements during and after pregnancy: a randomized placebo-controlled trial. Clinical Nutrition, 30, 156-64.
 
[41]  Sadrzadeh-Yeganeh, H., Elmadfa, I., Djazayery, A., Jalali, M., Heshmat, R., Chamary, M. The effects of probiotic and conventional yoghurt on lipid profile in women. British Journal of Nutrition, 103, 1778-83. 2010.
 
[42]  Ejtahed, H.S., Mohtadi-Nia, J., Homayouni-Rad, A., Niafar, M., Asghari-Jafarabadi, M., Mofid, V., Akbarian-Moghari, A. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. Journal of Dairy Sciences, 94, 3288-94. 2011.
 
[43]  Ejtahed, H.S., Mohtadi-Nia, J., Homayouni-Rad, A., Niafar, M., Asghari-Jafarabadi, M., Mofid, V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition, 28, 539-43. 2012.
 
[44]  Nockher, W.A., Scherberich, J.E. Monocyte cell-surface CD14 expression and soluble CD14 antigen in hemodialysis: evidence for chronic exposure to LPS. Kidney International, 48, 1469-76. 1995.
 
[45]  Hiki, N., Berger, D., Dentener, M.A., Mimura, Y., Buurman, M.A., Prigl, C., et al. Changes in endotoxin-binding proteins during major elective surgery: important role for soluble CD14 in regulation of biological activity of systemic endotoxin. Clinical and Diagnostic Laboratory Immunology, 6, 844-850. 1999.
 
[46]  Schiffrin, E.J., Thomas, D.R., Kumar, V.B., Brown, C., Hager, C., Van't Hof, M.A., Morley, J.E., Guigoz, Y. Systemic inflammatory markers in older persons: the effect of oral nutritional supplementation with prebiotics. Journal of Nutrition and Health Aging, 11, 475-9. 2007.
 
[47]  Schiffrin, E.J., Parlesak, A., Bode, C., Bode, J.C., van't Hof, M.A., Grathwohl, D., Guigoz, Y. Probiotic yogurt in the elderly with intestinal bacterial overgrowth: endotoxaemia and innate immune functions. British Journal of Nutrition, 101, 961-6. 2009.
 
[48]  Prescott, S.L., Wickens, K., Westcott, L., Jung, W., Currie, H., Black, PN., et al. Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferon-gamma and breast milk transforming growth factor-beta and immunoglobin A detection. Clinical and Experimental Allergy, 38, 1606-14. 2008.